By Carolyn Y. Johnson; The Washington Post ~ Oct 09, 2015
A political firestorm is building over the protections for drug companies in Obama administration’s massive international trade deal, threatening support for a key piece of the president’s legacy.
The chapter addressing the issue, which was posted online Friday by WikiLeaks, grants at least five years of exclusivity to the makers of next-generation biologic medicines for diseases ranging from cancer to rheumatoid arthritis.
